Pacific Biosciences Of California (PACB) EBIT Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -20.56% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 11.83% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 30.43% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 19.54% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 20.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 90.95% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 74.18% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -18.12% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Pacific Biosciences Of California | 428.15 Mn | 152.18 Mn | 12.84 Mn | 98.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98.05% |
| Dec 31, 2025 | 73.08% |
| Sep 30, 2025 | 39.33% |
| Jun 30, 2025 | 74.49% |
| Mar 31, 2025 | -427.19% |
| Dec 31, 2024 | -74.79% |
| Sep 30, 2024 | 22.32% |
| Jun 30, 2024 | -140.31% |
| Mar 31, 2024 | 10.84% |
| Dec 31, 2023 | -0.53% |
| Sep 30, 2023 | -10.55% |
| Jun 30, 2023 | -7.66% |
| Mar 31, 2023 | -17.71% |
| Dec 31, 2022 | -34.65% |
| Jun 30, 2022 | -80.90% |
| Mar 31, 2022 | -129.97% |
| Dec 31, 2021 | -169.74% |
| Jun 30, 2021 | -59.72% |
| Mar 31, 2021 | -3.06% |
| Dec 31, 2020 | -33.82% |